Skip to content
Agentic OS
Menu

Intelligence / Healthtech / De Novo Grants / Biolinq Incorporated

Approvalsnovel device granted (FDA De Novo)23 Sept 2025

Biolinq Incorporated

23 Sept 2025: Novel device granted (FDA De Novo) · Biolinq Shine Autonomous Time-in-Range Microsensor. Recorded in the openFDA device 510(k) (De Novo decisions).

View the source record

Granted
23 Sept 2025
Device
Biolinq Shine Autonomous Time-in-Range Microsensor
Specialty
Clinical Chemistry
Product Code
SFU
Country
United States
Location
San Diego, CA
Submitted
2024-12-27
Reference
DEN240080
What this signal means

A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.

  1. 2 added in the 30 days to 19 Nov 2026.
  2. Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS

Find the decision makers at Biolinq Incorporated

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Biolinq Incorporated in our registers.

More in Clinical Chemistry

De Novo Grants

See all

Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.